摘要
慢性血管疾病(CVD)应用抗血小板药物已经成为不可或缺的常规性辅助治疗方案,然而在使用抗血小板药物的患者中,发生抗血小板药物抵抗或出血风险等不良反应的情况时有发生,不但影响疗效,还会威胁患者的生命,抗血小板药物的安全性问题备受关注。临床资料表明患者的某些基因突变与治疗效果有明显的差异,细胞色素P450氧化酶2C19(CYP2C19)和载脂蛋白E(APOE)主要参与血小板活性和脂蛋白的转化与代谢过程,其基因突变是CVD患者抗血小板药物反应差异的重要机制之一,近年来CYP2C19、APOE基因突变在CVD中的表征及其与抗血小板药物研究取得许多新进展。
Antiplatelet drugs for chronic vas cular disease(CVD)have becom e an indispensable routine adjuvant treatment protocol.However,in patients who use antiplatelet drugs,adverse reactions such as resistance to antiplatelet drugs or the risk of bleeding often occur,not only affecting the efficacy,but also threatening the patient’s life.Therefore,the safety of antiplatelet drugs is of great concern.Clinical data shows that there are significant differences between certain gene mutations and treatment outcomes in patients with CVD.Cytochrome P450 oxidase 2C19(CYP2C19)and apolipoprotein E(APOE)are mainly involved in platelet activity and the transformation and metabolism of lipoproteins.Their gene mutations are one of the important mechanisms leading to the differences in antiplatelet drug responses in CVD patients.In recent years,the characterization of CYP2C19 and APOE gene mutations in CVD,and their association with antiplatelet drugs have made many new advances.
作者
赖腾芳
李近都
梁烨
李世龙
李天资
LAI Tengfang;LI Jindu;LIANG Ye;LI Shilong;LI Tianzi(Department of Cardiovascular Medicine,Affiliated Hospital of Youjiang Medical University for Nationalities,Guangxi,Baise 533000,China;Department of Hepatobiliary,Pancreas and Spleen Surgery,Guangxi Medical University Cancer Hospital,Guangxi,Nanning 530021,China;Department of Teaching,Affiliated Hospital of Youjiang Medical University for Nationalities,Guangxi,Baise 533000,China;Project Department,Guangxi Genliao Biotechnology Co.,Ltd.,Guangxi,Baise 533000,China)
出处
《中国医药科学》
2024年第13期24-28,共5页
China Medicine And Pharmacy
基金
广西重大专项计划(桂科1598005-9)
广西壮族自治区百色市科学与技术开发计划(百科20222940,百科20230512)。
